As Massachusetts prepares to vote on a measure that would legalize psilocybin and other plant-based psychedelic substances, ...

In the wake of Pfizer’s voluntary market withdrawal of the popular sickle cell disease therapy, BioSpace looks at five investigational drugs currently making their way through the pipeline.

Pharmaceutical companies are combining antibodies with radioisotopes in a bid to more precisely deliver radiation to cancers ...

VYLOY is the first and only CLDN18.2-targeted treatment approved in the U.S. for adults with advanced gastric and gastroesophageal junction cancer whose tumors are CLDN18.2 positive “While there have ...

This week marked the start of the third-quarter earnings season, with Johnson & Johnson exceeding Wall Street’s expectations.

The move is a blow to Gilead’s cancer portfolio. Trodelvy, an antibody-drug conjugate granted accelerated approval for ...

Merck’s investigational antibody clesrovimab demonstrated more than 60% effectiveness in reducing some types of respiratory ...

Pressure has been mounting for the Federal Trade Commission to take action, with Senator Elizabeth Warren last week urging ...

The regulator has delayed its respective decision dates on whether to grant full approval to Amgen’s Lumakras in metastatic ...

- Shared latest insights on brain image analysis used for prescription of Alzheimer’s disease treatments such as ‘Leqembi’ and ‘Kisunla’ This symposium was held at JW Marriott Hotel Seoul with the ...

Presentations Highlight the Unique Benefits of Real-world Utilization of INTERCEPT-treated Blood Products, Including INTERCEPT Fibrinogen Complex, and Recent Findings from the Phase 3 ReCePI Clinical ...